Citation: | Junping Zhu, Ye Lin, Gejing Li, Yini He, Zhaoli Su, Yuanyuan Tang, Ye Zhang, Qian Xu, Zhongliu Yao, Hua Zhou, Bin Liu, Xiong Cai. Dual-targeted halofuginone hydrobromide nanocomplexes for promotion of macrophage repolarization and apoptosis of rheumatoid arthritis fibroblast-like synoviocytes in adjuvant-induced arthritis in rats[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2024.100981 |
[1] |
A. Di Matteo, J.M. Bathon, P. Emery, Rheumatoid arthritis, Lancet. 402(2023)2019-2033.
|
[2] |
Y. Ma, Z. Lu, B. Jia, et al., DNA origami as a nanomedicine for targeted rheumatoid arthritis therapy through reactive oxygen species and nitric oxide scavenging, ACS Nano. 16(2022)12520-12531.
|
[3] |
E.M.L. Philippon, L.J.E. van Rooijen, F. Khodadust, et al., A novel 3D spheroid model of rheumatoid arthritis synovial tissue incorporating fibroblasts, endothelial cells, and macrophages, Front. Immunol. 14(2023), 1188835.
|
[4] |
J. Tu, X. Wang, X. Gong, et al., Synovial macrophages in rheumatoid arthritis:The past, present, and future, Mediators Inflamm. 2020(2020), 1583647.
|
[5] |
J. Zhu, J. Wei, Y. Lin, et al., Inhibition of IL-17 signaling in macrophages underlies the anti-arthritic effects of halofuginone hydrobromide:Network pharmacology, molecular docking, and experimental validation, BMC Complementary Med. Ther. 24(2024), 105.
|
[6] |
J. Smolen, R.B. Landewé, P. Mease, et al., Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis:The RAPID 2 study. A randomised controlled trial, Ann. Rheum. Dis. 68(2009)797-804.
|
[7] |
E. Berthet, M.De Rosa, P. Vorilhon, et al., AB1073 Exploration of the difficulties encountered by general practitioners with methotrexate and tnf-inhibitor treatment in common practice, Ann. Rheum. Dis. 75(2016), 1268.
|
[8] |
R.A. Moura, J.E. Fonseca, JAK inhibitors and modulation of B cell Immune responses in rheumatoid arthritis, Front. Med. 7(2021), 607725.
|
[9] |
M.K. Park, J.S. Park, E.M. Park, et al., Halofuginone ameliorates autoimmune arthritis in mice by regulating the balance between Th17 and Treg cells and inhibiting osteoclastogenesis, Arthritis Rheumatol. 66(2014)1195-1207.
|
[10] |
S. Zeng, K. Wang, M. Huang, et al., Halofuginone inhibits TNF-α-induced the migration and proliferation of fibroblast-like synoviocytes from rheumatoid arthritis patients, Int. Immunopharmacol. 43(2017)187-194.
|
[11] |
J. Gill, A. Sharma, Prospects of halofuginone as an antiprotozoal drug scaffold, Drug Discov. Today. 27(2022)2586-2592.
|
[12] |
K. Park, S. Skidmore, J. Hadar, et al., Injectable, long-acting PLGA formulations:Analyzing PLGA and understanding microparticle formation, J. Control. Release. 304(2019)125-134.
|
[13] |
J. Fan, Y. Qin, C. Xiao, et al., Biomimetic PLGA-based nanocomplexes for improved tumor penetration to enhance chemo-photodynamic therapy against metastasis of TNBC, Mater. Today Adv. 16(2022), 100289.
|
[14] |
J. Lu, X. Gao, S. Wang, et al., Advanced strategies to evade the mononuclear phagocyte system clearance of nanomaterials, Explor. Beijing China. 3(2023), 20220045.
|
[15] |
Z. Lei, J. Fan, X. Li, et al., Biomimetic graphene oxide quantum dots nanoparticles targeted photothermal-chemotherapy for gastric cancer, J. Drug Target. 31(2023)320-333.
|
[16] |
P. You, A. Mayier, H. Zhou, et al., Targeting and promoting atherosclerosis regression using hybrid membrane coated nanomaterials via alleviated inflammation and enhanced autophagy, Appl. Mater. Today. 26(2022), 101386.
|
[17] |
Y. Lin, O. Yi, M. Hu, et al., Multifunctional nanoparticles of sinomenine hydrochloride for treat-to-target therapy of rheumatoid arthritis via modulation of proinflammatory cytokines, J. Control. Release. 348(2022)42-56.
|
[18] |
M. Ge, C. Du, Preparation process of shear thickening gel based on constrained uniform mixture design and orthogonal experimental design, Polym. Test. 129(2023), 108267.
|
[19] |
B. Liu, W. Wang, J. Fan, et al., RBC membrane camouflaged prussian blue nanoparticles for gamabutolin loading and combined chemo/photothermal therapy of breast cancer, Biomaterials. 217(2019), 119301.
|
[20] |
C. He, W. Quan, Y. Zeng, et al., Construction of nicotinic acid curcumin nanoparticles and its Anti-atherosclerosis effect via PCSK9/LDL-R, ABCA1/Caveolin-1/LXR pathway, Mater. Des. 229(2023), 111931.
|
[21] |
L. Concha, A.L. Resende Pires, A.M. Moraes, et al., Cost function analysis applied to different kinetic release models of Arrabidaea chica verlot extract from chitosan/alginate membranes, Polymers. 14(2022), 1109.
|
[22] |
P. You, A. Yang, Y. Sun, et al., Pro-efferocytosis biomimetic nanocomplexes for targeted atherosclerosis therapy through promoting macrophage re-polarization and inhibiting senescence, Mater. Des. 234(2023), 112316.
|
[23] |
S. Hu, Y. Lin, C. Tong, et al., A pH-Driven indomethacin-loaded nanomedicine for effective rheumatoid arthritis therapy by combining with photothermal therapy, J. Drug Target. 30(2022)737-752.
|
[24] |
S. Alivernini, L. MacDonald, A. Elmesmari, et al., Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis, Nat. Med. 26(2020)1295-1306.
|
[25] |
S. Tardito, G. Martinelli, S. Soldano, et al., Macrophage M1/M2 polarization and rheumatoid arthritis:A systematic review, Autoimmun. Rev. 18(2019), 102397.
|
[26] |
M. Hu, Z. Yao, L. Xu, et al., M2 macrophage polarization in systemic sclerosis fibrosis:Pathogenic mechanisms and therapeutic effects, Heliyon. 9(2023), e16206.
|
[27] |
H. Li, Y. Feng, X. Zheng, et al., M2-type exosomes nanoparticles for rheumatoid arthritis therapy via macrophage re-polarization, J. Control. Release. 341(2022)16-30.
|
[28] |
M. Noack, P. Miossec, Selected cytokine pathways in rheumatoid arthritis, Semin. Immunopathol. 39(2017)365-383.
|
[29] |
T. Huang, N. Mu, J. Gu, et al., DDR2-CYR61-MMP1 signaling pathway promotes bone erosion in rheumatoid arthritis through regulating migration and invasion of fibroblast-like synoviocytes, J. Bone Miner. Res. 34(2019)779-780.
|
[30] |
P.D. Katsikis, C.Q. Chu, F.M. Brennan, et al., Immunoregulatory role of interleukin 10 in rheumatoid arthritis, J. Exp. Med. 179(1994)1517-1527.
|
[31] |
H. Matsumoto, Y. Fujita, T. Asano, et al., Association between inflammatory cytokines and immune-checkpoint molecule in rheumatoid arthritis, PLoS One. 16(2021), e0260254.
|
[32] |
K.S. Nandakumar, Q. Fang, I. Wingbro Ågren, et al., Aberrant activation of immune and non-immune cells contributes to joint inflammation and bone degradation in rheumatoid arthritis, Int. J. Mol. Sci. 24(2023), 15883.
|
[33] |
J.G. Navashenaq, A.G. Shabgah, M. Hedayati-Moghadam, et al., The role of myeloid-derived suppressor cells in rheumatoid arthritis:An update, Life Sci. 269(2021), 119083.
|
[34] |
H.J. Kim, B. Ohk, H.J. Yoon, et al., Docosahexaenoic acid signaling attenuates the proliferation and differentiation of bone marrow-derived osteoclast precursors and promotes apoptosis in mature osteoclasts, Cell. Signal. 29(2017)226-232.
|
[35] |
I.P. Perpétuo, J. Caetano-Lopes, A.M. Rodrigues, et al., Effect of tumor necrosis factor inhibitor therapy on osteoclasts precursors in rheumatoid arthritis, BioMed Res. Int. 2017(2017), 2690402.
|
[36] |
K.A. Lee, K.W. Kim, B.M. Kim, et al., Promotion of osteoclastogenesis by IL-26 in rheumatoid arthritis, Arthritis Res. Ther. 21(2019), 283.
|
[37] |
J.S. Smolen, R.B.M. Landewé, J.W.J. Bijlsma, et al., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs:2019 update, Ann. Rheum. Dis. 79(2020)685-699.
|
[38] |
X. Zhang, Y. Liu, W. Liu, et al., Macrophage-hitchhiking interleukin-10 plasmid DNA delivery system modulates rheumatoid arthritis microenvironment via the re-polarization of macrophages, Nano Today. 54(2024), 102068.
|
[39] |
S. Li, J. Li, Y. Zhao, et al., Supramolecular integration of multifunctional nanomaterial by mannose-decorated azocalixarene with ginsenoside Rb1 for synergistic therapy of rheumatoid arthritis, ACS Nano. 17(2023)25468-25482.
|
[40] |
Z. Tang, S. Meng, X. Yang, et al., Neutrophil-mimetic, ROS responsive, and oxygen generating nanovesicles for targeted interventions of refractory rheumatoid arthritis, Small.(2023), e2307379.
|
[41] |
C. Tao, F. Li, Z. Ma, et al., Highly efficient oral iguratimod/polyvinyl alcohol nanodrugs fabricated by high-gravity nanoprecipitation technique for treatment of rheumatoid arthritis, Small.(2023), e2304150.
|
[42] |
D. Kim, J. Park, Y. Kang, et al., Drug repositioning of metformin encapsulated in PLGA combined with photothermal therapy ameliorates rheumatoid arthritis, Int. J. Nanomedicine. 18(2023)7267-7285.
|
[43] |
T. Puidokas, M. Kubilius, A. Stumbras, et al., Effect of leukocytes included in platelet concentrates on cell behaviour, Platelets. 30(2019)937-945.
|
[44] |
A. Nakashima, K. Suzuki, H. Fujii, et al., pos0527 acute kidney injury (aki) in patients with rheumatoid arthritis (RA), Ann. Rheum. Dis. 80(2021), 497.
|